Physician profile
Sarah E Sagorsky
NPI 1881826345
$68,057.60
in general payments reported to CMS, 2019-2025
21 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,679 · 2023: $29K · 2024: $13K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $16K · Travel and Lodging: $9,899 · Honoraria: $6,900 · Food and Beverage: $4,957 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,042.50 |
| Consulting Fee | $15,574.50 |
| Travel and Lodging | $9,898.98 |
| Honoraria | $6,900.00 |
| Food and Beverage | $4,957.48 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26,302.46 | 2023-2025 | |
| Mirati Therapeutics, INC. | $24,191.14 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $4,507.12 | 2023 | |
| Janssen Biotech, INC. | $2,595.26 | 2025 | Rybrevant |
| Array Biopharma INC | $2,240.47 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Daiichi Sankyo INC. | $1,373.46 | 2023-2025 | Enhertu |
| G1 Therapeutics, INC. | $1,365.40 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $1,158.09 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,050.00 | 2023 | Gilotrif |
| Astrazeneca Pharmaceuticals Lp | $999.43 | 2023-2025 | Lynparza, Imfinzi, Tagrisso |
| Janssen Global Services, LLC | $900.00 | 2025 | Rybrevant |
| Nuvation Bio INC. | $735.00 | 2025 | Ibtrozi |
| Novocure Gmbh | $200.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.95 | 2025 | |
| Genentech USA, INC. | $135.99 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.93 | 2023-2025 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $24.26 | 2025 | Libtayo |
| Eisai INC. | $21.63 | 2025 | |
| Amgen INC. | $21.44 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.68 | 2023 | |
| Btg International INC. | $15.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Sagorsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.